United Kingdom·Stock·London Stock ExchangeHaleon plc (HLN.L)
Health Care · Drug Manufacturers - Specialty & Generic · Europe
Price in GBP, last 5 years
- Last price
- £3.80 (Oct 22, 2026)
- 1-year return
- +7.1%
- 3-year annual return
- +4.2%
- 5-year annual return
- —
- 1-year volatility
- 22.7%
- Max drawdown (5Y)
- -22.7%
- Market cap (approx.)
- US$44.6B
- History available
- since Jul 18, 2022
About Haleon plc
Haleon plc (HLN.L) is a stock from the United Kingdom that trades on London Stock Exchange in GBP. It operates in the health care sector, Drug Manufacturers - Specialty & Generic industry. It's part of the FTSE 100.
Over the last year its price rose 7.1% in GBP, with annual volatility of 23%: a moderately volatile asset. Its worst drop over the last five years was 22.7% from a peak.
If your currency isn't the GBP, your real return will also depend on the exchange rate. In the optimizer you can choose your currency (USD, EUR, MXN, BRL, CLP, COP, PEN or ARS) and the calculation includes that currency risk.
How does it fit into a portfolio? What matters is not just its risk on its own, but how much it moves together with your other assets. Add it to your list and the optimizer will show you what weight the model would give it and why.
Other health care assets in Europe
| Asset | 1 year | 1Y return | Volatility | Market cap | |
|---|---|---|---|---|---|
 Roche Holding AGROP.SW · Stock · Health Care | +43.5% | 24% | US$378.1B | ||
Novartis AGNOVN.SW · Stock · Health Care | +26.6% | 23% | US$298.0B | ||
AstraZeneca PLCAZN.L · Stock · Health Care | +2.8% | 27% | US$266.9B | ||
GSK plcGSK.L · Stock · Health Care | +14.9% | 25% | US$101.6B | ||
 SanofiSAN.PA · Stock · Health Care | -9.7% | 22% | US$99.9B | ||
EssilorLuxottica Société anonymeEL.PA · Stock · Health Care | -42.3% | 33% | US$90.1B | ||
 argenx SEARGX.BR · Stock · Health Care | +12.2% | 40% | US$56.1B | ||
Lonza Group AGLONN.SW · Stock · Health Care | +13.6% | 23% | US$53.4B |
Disclaimer: Educational and simulation tool. It is not investment advice or a personalized recommendation. Past performance does not guarantee future results. Data for educational purposes; it may be delayed or contain errors.